Latest News & Features
Big Pharma
There still are some cultural, legal and procedural barriers that must be overcome before the potential of Brazil’s life sciences sector can be realised, as Gabriel Di Blasi and Mellina Mamede of Di Blasi, Parente & Associados explain. 27 November 2014
article
The Indian Patent Office has issued guidelines aimed at bringing together the intentions of the Patents Act and the Biological Diversity Act, but this has posed serious challenges in obtaining patent protection, say Ranjna Mehta-Dutt and Neha Srivastava of Remfry & Sagar. 27 November 2014
Big Pharma
The current regulations in Mexico provide a legal framework for protecting genetic resources, but the framework for investing in new biotechnology is still not clear, as Karla Roxana Aispuro Castro and Mariana González Vargas of Becerril, Coca & Becerril report. 27 November 2014
Europe
The EPO’s Enlarged Board of Appeal is about to deliver its long-awaited final decision on the patentability of plants, in the hope that it will at least bring legal certainty to patentees and unfreeze pending appeals. Franz-Josef Zimmer and Markus Grammel of Grünecker report. 27 November 2014
Big Pharma
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP. 26 November 2014
Big Pharma
A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports. 25 November 2014
Biotechnology
Earlier this year, the Advocate General of
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion. 4 November 2014
Big Pharma
Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft. 4 November 2014
Americas
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi. 4 November 2014
Europe
Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy. 3 November 2014